An abdominal aortic aneurysm (AAA) is a permanent, localized dilatation of the abdominal aorta. In western countries, the morbidity of AAA is approximately 8%. Currently, pharmacotherapies for AAA are limited. Here, we demonstrate that baicalein (BAI), the main component of the Chinese traditional drug "Huang Qin", attenuates the incidence and severity of AAA in Apoe / mice infused with angiotensin II (AngII). Mechanically, BAI treatment decreases AngII-induced reactive oxygen species (ROS) production in the aortic wall. Moreover, BAI inhibits inflammatory cell accumulation in the aortas of mice infused with AngII. It also inhibits AngII-induced activation of matrix metalloproteinase 2 (MMP-2) and MMP-9 to maintain elastin content in vivo. In addition, it blocks AngII cascade by downregulating angiotensin type 1 receptor (AT1R) and inhibiting mitogen-activated protein kinases (MAPKs). Taken together, our findings show that BAI is an effective agent for AAA prevention. 
INTRODUCTION
An abdominal aortic aneurysm (AAA) is defined as a permanent, localized dilatation of the abdominal aorta to 1.5-fold more than the normal diameter. In western countries, the morbidity of AAA is approximately 8%. Owing to the lack of typical syndrome, the mortality rate associated with aortic rupture exceeds 80% (Nordon et al., 2011; Sakalihasan et al., 2005) . Currently, AAA therapies mainly include pharmacotherapy and surgical approaches (open repair and endovascular aneurysm repair) (Brewster et al., 2003) . The chief function of pharmacotherapy, which controls the risk factors, is to indirectly attenuate aneurysm development and aorta rupture by regulating blood pressure, serum lipid level, and blood coagulation (Bergoeing et al., 2006; Miyake and Morishita, 2009) . Therefore, developing new drugs that target the mechanism of AAA development is of great significance to AAA prevention and treatment.
The involved pathophysiological processes mainly include oxidative stress, vascular inflammation, and extracellular matrix degradation (Lopez-Candales et al., 1997; Thompson et al., 1997 Thompson et al., , 2002 . Apoe / mice infused with angiotensin II (AngII) is the most commonly employed animal model to study the pathogenesis of AAA since it mimics almost all the clinical characteristics of human AAA (Daugherty and Cassis, 2004; Weiss et al., 2001) . Notably, AngII cascade is upregulated in human AAA samples (Annambhotla et al., 2008; Golledge and Powell, 2007) . Baicalein (BAI) , which is involved in oxidative stress, inflammation, tumorigenesis, and angiogenesisis, is the main component of the Chinese traditional drug "Huang Qin", (Gao et al., 1999) . It has been reported that BAI remarkably retards is chemia/reperfusion-induced myocardium injury (Liu et al., 2013; Wang et al., 2013) . However, its exact mechanism remains elusive and its role in AAA development has not been elucidated.
In the present study, we examined the role of BAI in AAA induced by AngII treatment in Apoe / mice. From the view of oxidative stress, vascular inflammation, and extracellular matrix degradation, the relevant mechanisms were studied. The AngII cascade activation was also evaluated under BAI treatment. We believe that our findings may provide a new drug for AAA prevention and treatment.
RESULTS

BAI decreases AAA incidence in vivo
BAI did not alter the gross morphology of the aortas in Apoe / mice ( Figure 1A ). Consistent with previous findings (Satoh et al., 2009; Wang et al., 2012) , the incidence of AAA in Apoe / mice treated with vehicle after AngII infusion for 4 weeks was 88% in our study. In contrast, only 47% of BAI-treated Apoe / mice developed AAA after AngII treatment ( Figure 1B) . No AAAs were detected in saline-infused mice.
BAI attenuated AAA severity (the ratio of aorta weight to body weight and maximal abdominal aortic diameter) in vivo
The maximal abdominal aortic diameter and the total aortic weight significantly increased after AngII infusion for 4 weeks in all groups compared to that in saline-infused mice.
Compared to AngII-infused mice treated with vehicle, the BAI-treated mice had decreased maximal abdominal aortic diameter and total aortic weight (Figure 2A-C) . As shown in Tables 1 and 2 , SBP, HR, and serum lipid levels did not differ between Apoe / mice treated with BAI and those receiving vehicle after AngII infusion for 4 weeks. Taken together, BAI represses AngII-induced AAA in vivo, but it did not affect hemodynamic and lipid metabolic indices.
BAI treatment attenuated AngII-induced ROS production in vivo
Since oxidative stress is critical in AAA formation (Satoh et al., 2009; Thomas et al., 2006) , we first determined the oxi- dative stress-related parameters in vivo. We analyzed vascular ROS production by quantification of dihydroethidine hydrochloride (DHE) staining. DHE-positive staining was rarely detected in the suprarenal aortic wall of salineinfused mice. AngII infusion markedly increased the level of ROS production in Apoe / mice. However, densitometric analysis of DHE staining showed reduced staining in the suprarenal aortic wall of BAI-treated Apoe / mice ( Figure   3A and B). Collectively, BAI ameliorates AngII-induced ROS in vivo.
BAI treatment decreased AngII-induced vascular inflammation in vivo
Vascular inflammation is implicated in AAA development, which is correlated with ROS production and MMP activation (Hellenthal et al., 2009b; Thompson et al., 2002) . Few inflammatory cells were found in the suprarenal aortic wall of saline-infused mice. After AngII infusion, a large number of inflammatory cells, as determined by CD45 immunostaining, accumulated in the aortic wall especially in the adventitia of Apoe / mice. However, the number of inflammatory cells was remarkably lower in the suprarenal aortic wall of AngII-infused Apoe / mice after BAI treatment ( Figure 4A and B), than that after vehicle treatment.
BAI treatment inhibited AngII-induced MMP-2 and MMP-9 activation to maintain elastin content in vivo
Vascular smooth muscle cell (VSMC)-derived MMP-2 and macrophage-derived MMP-9 are considered as key factors in extracellular matrix degradation that is crucial for AAA development and aortic rupture (Longo et al., 2002) . First, we examined the activity of MMP-2 and MMP-9 in aorta homogenates by gelatin zymography. AngII infusion remarkably induced MMP-2 activation (14.6-fold increase on an average) and MMP-9 activation (2.7-fold increase on an average) in Apoe / mice; a lower degree of activation was observed in BAI-treated Apoe / mice (MMP-2: 6.1-fold increase on an average; MMP-9: 1.9-fold increase on an average; Figure 5A -C). The expression of MMP-2 and MMP-9 markedly increased in AngII-infused Apoe / mice.
In contrast to the results obtained for vehicle groups, BAI treatment reduced MMP-2 and MMP-9 protein level after AngII treatment ( Figure 5A , D and E). Next, medial elastin content was measured to detect extracellular matrix degradation. A marked decrease in aortic elastic fiber content was detected after AngII infusion for 4 weeks relative to saline-infused mice. However, the elastin fiber content in the suprarenal aortas of BAI-treated mice after AngII infusion was significantly higher than that in vehicle-treated mice ( Figure 6A and B). Taken together, these in vivo data suggest that AngII-induced MMP activation and extracellular matrix degradation are inhibited by BAI.
BAI treatment blocked p38-mitogen activated protein kinase (MAPK) and JNK signaling pathways by downregulating AT1R in vivo
The physiological and pathological effects of AngII are mainly mediated by its receptors, AT1R and AT2R (Mehta and Griendling, 2007) . Thus, we examined whether BAI-treatment could influence the level of AngII receptors in mouse aorta. The data in Figure 7A -C shows that the protein level of AT1R was repressed after BAI treatment in the aortas of both saline-or AngII-infused Apoe / mice.
However, the AT2R expression was not affected by BAI administration. Next, we determined the downstream sig- 
8A-D). In summary, BAI inhibits AngII cell signaling by downregulating AT1R in vivo.
DISCUSSION
In this study, we showed for the first time that BAI protects against AngII-induced AAA in Apoe / mice. BAI treatment significantly reduces AAA incidence and aorta dilatation in vivo. Mechanically, it attenuates AngII-induced oxidative stress, vascular inflammation, and extracellular matrix degradation. Moreover, it inhibits JNK and p38-MAPK signaling by AT1R downregulation (summarized in Figure 9 ). Our findings suggest a new agent for AAA pharmacotherapy. Currently, there is no effective pharmacological therapy to prevent or suppress AAA development and progression. Intraperitoneal injection of BAI (30 mg kg 1 day 1 ) markedly reduced the incidence of AAA in AngII-infused Apoe / mice. More importantly, the severity of AAA (the ratio of aorta weight to body weight and maximal abdominal aortic diameter) decreased in response to BAI treatment in AngII-infused mice, suggesting that BAI protects against not only AAA initiation but also its progression. Augmented oxidative stress plays a vital role in AAA development (Keaney, 2005; Zhang et al., 2003) . In the present study, we found that ROS production as examined by DHE staining was inhibited in mouse aortas after BAI treatment. The mechanisms underlying the antioxidant effect of BAI mainly include ROS scavenging and decreased ROS production (Gao et al., 1999; Kang et al., 2012; Shao et al., 1999) . Moreover, oxidative stress is closely associated with inflammation and MMP activation (Hellenthal et al., 2009a, b) . For example, the expression of monocyte chemotactic protein 1 (MCP-1) and MMP-2 is partly regulated by some redox-sensitive transcriptional factors such as nuclear factor (NF)-B (Finkel and Holbrook, 2000) . Thus, decreased ROS production leads to the inhibition of subsequent inflammation and extracellular matrix degradation. As shown in our figures, inflammatory cell accumulation in aortic wall is attenuated by BAI treatment. According to our data, inflammatory cells are mainly localized in vascular adventitia, indicating that the cells may be from the blood circulation. Previous reported data show that the majority of ROS is secreted by inflammatory cells such as monocytes and macrophages (Thompson et al., 2002) . Thus, BAI-induced attenuation of inflammation also results in decreased ROS production. During AAA development, the vascular wall stress increases following extra cellular matrix degradation, which leads to the final aortic rupture (Vorp, 2007) . VSMC-derived MMP-2 and macrophage-derived MMP-9 are of great importance in the process of ECM degradation (Galis and Khatri, 2002; Longo et al., 2002) . Our data show that both the expression and the activity of MMP-2 and MMP-9 are inhibited by BAI treatment, indicating that the main target of BAI may be VSMCs and macrophages. These effects of BAI result in the preservation of the wavy structure of the elastic lamellae and the elastic content to prevent AAA development and aortic rupture. The majority of the known effects of AngII are mediated by AT1Rs, which are widely distributed in the lung, kidney, and heart. While the majority of the vasoactive effects of AngII occur via AT1Rs, AT2Rs have been shown to have anti-proliferative and pro-apoptotic effects in VSMCs, mainly by antagonizing AT1Rs (Griendling et al., 1996) . Our data show that in saline-and AngII-infused aortas, AT1R but not AT2R is downregulated with BAI treatment, resulting in AngII cascade blockade. For the downstream signaling pathways, we examined MAPK activation in vivo, which is implicated in cellular protein synthesis, gene expression, metabolism, and growth. Interestingly, JNK and p38-MAPK but not Erk pathways were downregulated following BAI treatment. It has been reported that inhibition of JNK pathway prevents AAA development through MMP-2 and MMP-9 suppression (Yoshimura et al., 2005) . Our results and previous data indicate that MAPK signaling pathways could be considered novel therapeutic targets of AAA treatment.
In conclusion, BAI treatment in Apoe / mice inhibits AAA formation induced by AngII infusion and is associated with a reduction of oxidative stress, vascular inflammation, and ECM degradation. The effects of BAI are mediated by the inhibition of JNK and p38-MAPK pathways through AT1R downregulation. Our findings represent novel therapeutic agent particularly for prevention of AAA initiation and progression.
MATERIALS AND METHODS
Generation of mice
All the animal protocols were approved by the Animal Care and Use Committee at the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC). The Apoe / and C57BL/6J mice were obtained from Peking University (Beijing).
Blood pressure and serum lipid measurements
Heart rate (HR) and systolic blood pressure (SBP) of the animals were measured using tail-cuff plethysmography (BP-2000 System, Visitech Systems, Apex, USA) as described previously (Li et al., 2011) . Blood samples were obtained from the mice before sacrifice. The blood was collected from the abdominal vena cava at sacrifice. Serum cholesterol, triglyceride, high-density lipoproteincholesterol (HDL-C), and low-density lipoproteincholesterol (LDL-C) were measured at the clinical laboratory of Peking Union Medical College Hospital.
Analyses and quantification of AAA
Four-to 6-month-old male mice fed a normal chow diet were used. All the mice were infused with AngII (Sigma-Aldrich, A9525, USA) at 1.44 mg kg 1 day 1 or saline for 4 weeks by using Alzet osmotic pumps (model 2004, DURECT Corp., USA). The experiments were performed as previously described (Satoh et al., 2009 ). An aortic aneurysm is defined as the increase in the external width of the suprarenal aorta by 50% or greater compared with that in saline-infused mice. The maximum width of the abdominal aorta was analyzed with Image Pro Plus software (Media Cybernetics). 
BAI treatment
Histological analyses
After hemodynamic measurements, the animals were sacrificed. For morphological analysis, the aortas were perfused with normal saline and fixed with 10% phosphate buffer saline (PBS) and formalin at physiological pressure for 5 min. The whole aortas were harvested, fixed for 24 h, embedded in paraffin, and cross-sections (5 µm) were prepared. Paraffin sections were stained with elastin van Gieson, H&E, or used for immunostaining.
Immunohistochemistry
Slides were deparaffinized, and endogenous peroxidase activity was quenched with 3% (v/v) hydrogen peroxide in 10% PBS for 10 min. Nonspecific binding sites were blocked with 10% bovine serum in PBS at room temperature for 1 h. Slides were incubated at 4°C overnight with diluted primary antibodies, then with biotinylated secondary antibody at 37°C for 30 min, and subsequently with horseradish peroxidase-labeled streptavidin solution for 20 min at 37°C. Slides were then stained with diaminobenzidine and counterstained with hematoxylin. The primary antibody used was CD45 (clone Ly-5, 1 : 100 dilution; BD Pharmingen, USA). A mean value was determined from at least 4 sections in each animal.
Western blot analyses
Western blots were performed as described previously (Zhou et al., 2011 
Matrix metalloproteinase (MMP) activity
The detection of MMP-2 and MMP-9 activity was performed as previously reported (Hawkes et al., 2010) . Five micrograms of protein in the concentrated aortic homogenates was electrophoresed on SDS-PAGE gels containing gelatin. Gels were washed in 2.5% Triton X-100 for 30 min and incubated for 12-40 h with zymography development buffer at 37°C. Subsequently, the gel was stained with Coomassie brilliant blue.
ROS analysis
The aortic tissue was harvested, and the suprarenal abdominal aorta were embedded in OCT (C1400, APPLYGEN, Beijing) and snap-frozen. DHE (5 µmol L 1 , D-23107, Molecular Probes, USA) was topically applied to the freshly cut, frozen aortic sections (10 µm) for 30 min at 37°C to detect the presence of ROS as red fluorescence (585 nm) by confocal microscopy (Olympus).
Statistical analyses
Quantitative results are expressed as the mean±SE. Fisher's exact test was applied to the comparisons of AAA incidence and mortality. Comparisons of parameters between two groups were performed using the unpaired Student t-test or a nonparametric test. Comparisons of parameters between more than two groups were performed by one-way ANOVA, and comparisons of different parameters between each group were made by a post hoc analysis using the Bonferroni test. Statistical significance was evaluated with GraphPad Prism 5. A P value less than 0.05 was considered statistically significant.
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